ALK-Abelló A/S
CPH: ALK-B.CO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Copenhagen
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Peter Halling
- Employees
- 2,736
- Headquarters
- Horsholm, Denmark
- IPO year
- 2000
- Market cap
- DKK 56.6B
- Website
- https://www.alk.net
Loading ALK-B…
Loading profile data…Frequently asked questions about ALK-B
What does ALK-Abelló A/S (ALK-B.CO) do?
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. It product portfolio include GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDACURE, and ITULAZAX for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injectio...
Where does ALK-B.CO trade?
ALK-Abelló A/S (ALK-B.CO) trades on the NASDAQ Copenhagen.
What sector is ALK-B.CO in?
ALK-Abelló A/S (ALK-B.CO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of ALK-Abelló A/S?
Peter Halling is the chief executive officer of ALK-Abelló A/S (ALK-B.CO).
Where is ALK-Abelló A/S headquartered?
ALK-Abelló A/S is headquartered in Denmark.
Does ALK-B.CO pay a dividend?
Yes — ALK-Abelló A/S (ALK-B.CO) paid a trailing twelve-month dividend of DKK 1.60 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did ALK-B.CO go public?
ALK-Abelló A/S (ALK-B.CO) completed its initial public offering in 2000.